Ruxolitinib in Chronic Myelomonocytic Leukemia (CMML)

Current understanding

Ruxolitinib, a JAK1/2 inhibitor established in myelofibrosis and PV, is being evaluated in a Phase 2 expansion trial for chronic myelomonocytic leukemia (CMML), a MDS/MPN overlap disorder frequently associated with GM-CSF hypersensitivity and JAK-STAT activation. Early-phase trial evidence is anticipated to clarify whether JAK inhibition can meaningfully reduce splenomegaly, constitutional symptoms, and inflammatory burden in CMML, where treatment options remain limited outside hypomethylating agents and transplant.

Evidence log

• 2026-07-15 — Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML): cross-connection with axatilimab-csf1r-mf-cmml: Trial includes CMML as an indication, overlapping with the ruxolitinib-in-CMML expansion population and offering a rationale for CSF1R + JAK co-targeting in monocyte-driven disease. (novelty: 3)
• 2026-06-16 — Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.: cross-connection with azacitidine-ruxolitinib-combination: MDS/MPN activity signal from the aza+rux Phase 2 complements single-agent ruxolitinib data in CMML, suggesting HMA add-on as a route to deepen responses in overlap syndromes. (novelty: 3)
• 2026-07-01 — Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.: cross-connection with selinexor-azacitidine-combination: MDS/MPN overlap trial connects selinexor+azacitidine to the CMML/overlap-syndrome therapeutic space where ruxolitinib is also being explored, framing XPO1+HMA as an alternative to JAK-inhibitor-based overlap regimens. (novelty: 3)
• 2026-07-01 — Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion: cross-connection with azacitidine-venetoclax-cmml: Both represent emerging systemic therapy approaches in higher-risk CMML, positioning JAK inhibition alongside HMA + BCL-2 inhibitor combinations in the CMML treatment landscape. (novelty: 3)

Open questions

Related